The EHMT2 Knockout UM-UC-3 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the UM-UC-3 human bladder transitional cell carcinoma cell line, featuring disruption of the endogenous EHMT2 gene. This product provides a loss-of-function model system that enables researchers to interrogate the roles of EHMT2-mediated histone methylation in cancer biology without selection of a monoclonal isolate, preserving the inherent heterogeneity of the polyclonal pool for robust experimental comparisons against parental controls.
The UM-UC-3 cell line was originally established from a primary human bladder transitional cell carcinoma and serves as a well-characterized, tumorigenic epithelial model for studying urothelial cancer pathogenesis. These adherent cells exhibit features characteristic of high-grade bladder carcinoma, including deregulated cell cycle progression, anchorage-independent growth, and invasive potential, making them an appropriate platform for investigating the epigenetic mechanisms that drive malignant phenotypes in this tissue context.
EHMT2 (also known as G9a) is a histone methyltransferase that catalyzes mono- and dimethylation of histone H3 at lysine 9 (H3K9me1 and H3K9me2), establishing repressive chromatin marks associated with transcriptional silencing and heterochromatin formation. In UM-UC-3 cells, EHMT2 functions within a network regulated by MYC, HIF1A, E2F1, and CDK2, and it forms complexes with EHMT1 and WIZ to interact with DNMT1, UHRF1, PCNA, and SNAI1. Its enzymatic activity directly represses key downstream targets such as the cyclin-dependent kinase inhibitor CDKN1A, the cell adhesion molecule CDH1, the dual-specificity phosphatase DUSP5, and the pro-apoptotic factor BIM. Through modulation of H3K9 methylation, EHMT2 influences the Wnt/??-catenin pathway by regulating CTNNB1 expression and SFRP1 silencing, while also engaging HP1 to stabilize heterochromatin domains. CRISPR/Cas9-mediated disruption of EHMT2 is expected to abrogate these repressive activities.
In the context of bladder cancer, loss of EHMT2 function may restore expression of tumor suppressor genes such as CDKN1A and CDH1, leading to reduced cell proliferation, impaired migration, and enhanced apoptosis. The polyclonal knockout population provides a biologically relevant system in which the heterogeneity of editing events mimics the complex genetic landscape of tumors, offering a tool to dissect how epigenetic dysregulation contributes to bladder tumorigenesis and to screen for synthetic lethal interactions or chemosensitization effects.
These polyclonal knockout cells are suited for a wide range of applications, including quantitative analysis of H3K9 methylation dynamics by ChIP-qPCR or immunofluorescence, validation of EHMT2 as a therapeutic target in bladder cancer research, tumor suppressor reactivation assays via RT-qPCR or western blotting, and functional phenotyping through cell proliferation, colony formation, and migration assays. Transcriptomic profiling by RNA-seq can further elucidate global changes in gene expression resulting from EHMT2 loss. For additional product details, customization options, or technical assistance, please contact Ascent Research.
